30 June 2020 - Another lame response from PHARMAC.

PHARMAC has responded to an OIA request for information on the agency's funding of high cost medicines.

"We are unable to provide you with the pricing of the most expensive treatments in this categories because, where pricing is provided, it is commercially sensitive, confidential and, in some instances subject to negotiation, so is being withheld under sections 9(2)(b)(ii), 9(2)(ba)(i) and 9(2)(j) of the OIA. PHARMAC is unable to provide information on ‘retail’ price because in many cases the treatments are not available for retail sale at this time and, if they are, PHARMAC does not hold this information (section 18(g) of the OIA). Section 18(g) also applies in respect of information about the number of people that may benefit from each of these applications, because their inactivity means that any information would no longer be current."

Read PHARMAC OIA response